BioVie announced a registered direct offering of 2,667,000 common shares priced at $2.25 per share, aiming to raise approximately $6 million in gross proceeds. The offering, expected to close on October 24, 2024, is being conducted at-the-market under Nasdaq rules with ThinkEquity acting as the sole placement agent.In a concurrent private placement, the company will issue unregistered warrants to purchase up to 2,667,000 shares at an exercise price of $2.12 per share. These warrants will become exercisable six months from issuance and expire five years after the initial exercise date. Additionally, the placement agent received warrants to purchase 133,350 shares at $2.8125 per share.The company plans to use the net proceeds for working capital and general corporate purposes. The shares offering was made under BioVie's effective S-3 registration statement, while the warrants were offered through a private placement exempt from registration requirements under Securities Act Section 4(a)(2).

BioVie announced a registered direct offering of 2,667,000 common shares priced at $2.25 per share, aiming to raise approximately $6 million in gross proceeds. The offering, expected to close on October 24, 2024, is being conducted at-the-market under Nasdaq rules with ThinkEquity acting as the sole placement agent.In a concurrent private placement, the company will issue unregistered warrants to purchase up to 2,667,000 shares at an exercise price of $2.12 per share. These warrants will become exercisable six months from issuance and expire five years after the initial exercise date. Additionally, the placement agent received warrants to purchase 133,350 shares at $2.8125 per share.The company plans to use the net proceeds for working capital and general corporate purposes. The shares offering was made under BioVie's effective S-3 registration statement, while the warrants were offered through a private placement exempt from registration requirements under Securities Act Section 4(a)(2).